New Agents

323Background: Until few years ago, docetaxel (DOC) was the only agent able to significantly prolong overall survival (OS) of… Expand

5030Background: Abiraterone acetate (AA), cabazitaxel (CABA), and enzalutamide (ENZ) may prolong survival in mCRPC pts… Expand

Hormone receptor positive breast cancer (HR-positive BC) is the most frequent BC subtype (∼70%), with endocrine treatment… Expand

BACKGROUND Two new hormonal agents (NHAs), abiraterone and enzalutamide, and one chemotherapeutic agent, cabazitaxel (CABA… Expand

The use of new agents (NAs) such as bortezomib, thalidomide, and lenalidomide has extended the survival of patients with multiple… Expand

Therapy-related acute myeloid leukemia (tAML) is a rare but highly fatal complication of cytotoxic chemotherapy. Despite major… Expand

With the introduction of high-dose therapy and new agents, outcomes of treatment have improved considerably for patients with… Expand

In some parts of the world, SCC of the penis represents a significant health problem. Although in the early stages it can be… Expand

Fludarabine Monophosphate (FLU) is an adenosine analogue with a high-level of anti-leukemic activity in patients (pts) with CLL… Expand

Treatment programs for digestive diseases should be evaluated by randomized clinical trials. Under most circumstances, the best… Expand